MK-4101
(Synonyms: 5-(3,3-二氟环丁基)-3-[4-[4-甲基-5-[2-(三氟甲基)苯基]-4H-1,2,4-三唑-3-基]双环[2.2.2]辛烷-1-基]-1,2,4-恶二唑) 目录号 : GC13630
A Smoothened receptor antagonist
Cas No.:935273-79-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
IC50: 1.5 μmol/L for in mouse Light II cells by Gli_luc assay
MK-4101 is a Hedgehog (Hh) signaling pathway inhibitor.
Abnormal activation of the Hedgehog (Hh) signaling pathway is reported in the pathogenesis of various cancers, such as medulloblastoma and basal cell carcinoma.
In vitro: MK-4101 was found to target the Hh pathway in tumor cells, with the maximum inhibitory effect on Gli1. MK-4101 could also induce the deregulation of cell cycle and block of DNA replication in tumors. In addition, members of the IGF and Wnt signaling pathways were among the most highly deregulated genes by MK-4101, indicating that the interplay among Hh, IGF, and Wnt was critical in Hh-dependent tumorigenesis [1].
In vivo: In a previous study, using neonatally irradiated Ptch1(+/-) mice as a model of Hh-dependent tumors, the in vivo effects of MK-4101 was investigated for the treatment of medulloblastoma and basal cell carcinoma. Results showed a potent antitumor activity of MK-4101, achieved by the inhibition of proliferation and induction of extensive apoptosis. Moreover, beside antitumor activity on transplanted tumors, MK-4101 was found to be highly efficacious against primary medulloblastoma and basal cell carcinoma in the cerebellum and skin [1].
Clinical trial: Up to now, MK-4101 is still in the preclinical development stage.
Reference:
[1] Filocamo G et al. MK-4101, a Potent Inhibitor of the Hedgehog Pathway, Is Highly Active against Medulloblastoma and Basal Cell Carcinoma. Mol Cancer Ther. 2016 Jun;15(6):1177-89.
| Cas No. | 935273-79-3 | SDF | |
| 别名 | 5-(3,3-二氟环丁基)-3-[4-[4-甲基-5-[2-(三氟甲基)苯基]-4H-1,2,4-三唑-3-基]双环[2.2.2]辛烷-1-基]-1,2,4-恶二唑 | ||
| 化学名 | 5-(3,3-difluorocyclobutyl)-3-(4-(4-methyl-5-(2-(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-yl)bicyclo[2.2.2]octan-1-yl)-1,2,4-oxadiazole | ||
| Canonical SMILES | CN1C(C2=CC=CC=C2C(F)(F)F)=NN=C1C34CCC(CC4)(C5=NOC(C6CC(F)(F)C6)=N5)CC3 | ||
| 分子式 | C24H24F5N5O | 分子量 | 493.47 |
| 溶解度 | DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 30 mg/ml,Ethanol:PBS (pH 7.2) (1:8): 0.11 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0265 mL | 10.1323 mL | 20.2647 mL |
| 5 mM | 0.4053 mL | 2.0265 mL | 4.0529 mL |
| 10 mM | 0.2026 mL | 1.0132 mL | 2.0265 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。